ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Florida » Hematology Oncology

Top Hematology Oncology Prescribers in Florida

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
NORMAN PALGON M.D.

Hematology Oncology

7,129

$328K

428
399 are 65+

6%
patients receiving schedule two controlled substances

Avg: 16%

10%
patients receiving schedule three controlled substances

Avg: 7%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 20%

$46
Average prescription price

Avg: $460

SERGIO XIQUES M.D.

Hematology Oncology

5,832

$1.56M

749
722 are 65+

6%
patients receiving schedule two controlled substances

Avg: 16%

3%
patients receiving schedule three controlled substances

Avg: 7%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 20%

$268
Average prescription price

Avg: $460

ROBERT KILLEEN MD

Hematology Oncology

5,490

$386K

181
157 are 65+

23%
patients receiving schedule two controlled substances

Avg: 16%

9%
patients receiving schedule three controlled substances

Avg: 7%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

26%
prescriptions for brand name drugs

Avg: 20%

$70
Average prescription price

Avg: $460

GOTARDO RODRIGUES M.D.

Hematology Oncology

5,169

$1.9M

499
462 are 65+

4%
patients receiving schedule two controlled substances

Avg: 16%

0%
patients receiving schedule three controlled substances

Avg: 7%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

32%
prescriptions for brand name drugs

Avg: 20%

$368
Average prescription price

Avg: $460

STEVEN MORRIS M.D.

Hematology Oncology

4,742

$240K

274
236 are 65+

11%
patients receiving schedule two controlled substances

Avg: 16%

15%
patients receiving schedule three controlled substances

Avg: 7%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 20%

$51
Average prescription price

Avg: $460

MICHAELA SCOTT M.D.

Hematology Oncology

4,160

$523K

467
434 are 65+

9%
patients receiving schedule two controlled substances

Avg: 16%

8%
patients receiving schedule three controlled substances

Avg: 7%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 20%

$126
Average prescription price

Avg: $460

THOMAS TAN MD

Hematology Oncology

4,050

$853K

272
176 are 65+

26%
patients receiving schedule two controlled substances

Avg: 16%

24%
patients receiving schedule three controlled substances

Avg: 7%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 20%

$211
Average prescription price

Avg: $460

MARY JO VILLAR D.O.

Hematology Oncology

3,983

$1.1M

893
849 are 65+

5%
patients receiving schedule two controlled substances

Avg: 16%

11%
patients receiving schedule three controlled substances

Avg: 7%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

13%
prescriptions for brand name drugs

Avg: 20%

$277
Average prescription price

Avg: $460

LUIS RANGEL MD

Hematology Oncology

3,891

$1.65M

639
602 are 65+

2%
patients receiving schedule two controlled substances

Avg: 16%

3%
patients receiving schedule three controlled substances

Avg: 7%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 20%

$424
Average prescription price

Avg: $460

JAMES HARRIS M.D.

Hematology Oncology

3,243

$1.15M

304
265 are 65+

18%
patients receiving schedule two controlled substances

Avg: 16%

7%
patients receiving schedule three controlled substances

Avg: 7%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

32%
prescriptions for brand name drugs

Avg: 20%

$355
Average prescription price

Avg: $460

SHALINI MULAPARTHI MD

Hematology Oncology

2,837

$563K

266
228 are 65+

12%
patients receiving schedule two controlled substances

Avg: 16%

14%
patients receiving schedule three controlled substances

Avg: 7%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 20%

$198
Average prescription price

Avg: $460

EDUARDO GOMEZ MD

Hematology Oncology

2,752

$1.2M

432
413 are 65+

3%
patients receiving schedule two controlled substances

Avg: 16%

0%
patients receiving schedule three controlled substances

Avg: 7%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

15%
prescriptions for brand name drugs

Avg: 20%

$437
Average prescription price

Avg: $460

RAUL CASTILLO MD

Hematology Oncology

2,665

$1.55M

315
221 are 65+

20%
patients receiving schedule two controlled substances

Avg: 16%

17%
patients receiving schedule three controlled substances

Avg: 7%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 20%

$583
Average prescription price

Avg: $460

CARLOS MIDENCE MD

Hematology Oncology

2,656

$1.36M

410
371 are 65+

7%
patients receiving schedule two controlled substances

Avg: 16%

5%
patients receiving schedule three controlled substances

Avg: 7%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 20%

$514
Average prescription price

Avg: $460

JOLLY VARKI MD

Hematology Oncology

2,591

$1.64M

203
167 are 65+

12%
patients receiving schedule two controlled substances

Avg: 16%

0%
patients receiving schedule three controlled substances

Avg: 7%

11%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 20%

$633
Average prescription price

Avg: $460

STEVEN MAMUS M.D.

Hematology Oncology

2,548

$1.06M

353
300 are 65+

15%
patients receiving schedule two controlled substances

Avg: 16%

17%
patients receiving schedule three controlled substances

Avg: 7%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 20%

$416
Average prescription price

Avg: $460

VIKAS MALHOTRA M.D.

Hematology Oncology

2,480

$1M

442
365 are 65+

15%
patients receiving schedule two controlled substances

Avg: 16%

9%
patients receiving schedule three controlled substances

Avg: 7%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 20%

$405
Average prescription price

Avg: $460

AUREA TOMESKI M.D.

Hematology Oncology

2,413

$175K

177
170 are 65+

11%
patients receiving schedule two controlled substances

Avg: 16%

0%
patients receiving schedule three controlled substances

Avg: 7%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

26%
prescriptions for brand name drugs

Avg: 20%

$73
Average prescription price

Avg: $460

ANDREW SCHNEIDER M.D.

Hematology Oncology

2,380

$730K

389
344 are 65+

23%
patients receiving schedule two controlled substances

Avg: 16%

5%
patients receiving schedule three controlled substances

Avg: 7%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 20%

$307
Average prescription price

Avg: $460

CARLOS ALEMANY M.D.

Hematology Oncology

2,345

$1.04M

256
189 are 65+

26%
patients receiving schedule two controlled substances

Avg: 16%

5%
patients receiving schedule three controlled substances

Avg: 7%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 20%

$444
Average prescription price

Avg: $460

EDUARDO ACLE M.D.

Hematology Oncology

2,275

$1.06M

361
340 are 65+

7%
patients receiving schedule two controlled substances

Avg: 16%

0%
patients receiving schedule three controlled substances

Avg: 7%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 20%

$465
Average prescription price

Avg: $460

RAKESH ROHATGI M.D.

Hematology Oncology

2,223

$828K

401
371 are 65+

9%
patients receiving schedule two controlled substances

Avg: 16%

18%
patients receiving schedule three controlled substances

Avg: 7%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 20%

$373
Average prescription price

Avg: $460

ELISABETH MCKEEN M.D.

Hematology Oncology

2,212

$276K

377
324 are 65+

8%
patients receiving schedule two controlled substances

Avg: 16%

8%
patients receiving schedule three controlled substances

Avg: 7%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 20%

$125
Average prescription price

Avg: $460

JOSE MELO M.D.

Hematology Oncology

2,172

$980K

373
331 are 65+

9%
patients receiving schedule two controlled substances

Avg: 16%

5%
patients receiving schedule three controlled substances

Avg: 7%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 20%

$451
Average prescription price

Avg: $460

PATRICK ACEVEDO M.D.

Hematology Oncology

2,167

$923K

325
266 are 65+

27%
patients receiving schedule two controlled substances

Avg: 16%

10%
patients receiving schedule three controlled substances

Avg: 7%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 20%

$426
Average prescription price

Avg: $460

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank